AccScience Publishing / CP / Volume 6 / Issue 2 /
Submit to CP
Cite this article
1
Download
70
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Long non-coding RNA DARS-AS1 facilitates breast cancer progression by modulating the miR-6835-3p/ATF3 axis

Krishnamoorthy Vignesh1* ,  Pattusamy Thangamalar1
Show Less
1 Department of Noi Naadal, Government of Siddha Medical College, Tirunelveli, Tamil Nadu, India
CP 2024, 6(2), 2867
Submitted: 1 February 2024 | Accepted: 12 March 2024 | Published: 28 June 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

Long non-coding RNAs (lncRNAs) play crucial roles in various cellular processes associated with cancer progression, including invasion, proliferation, and metastasis. Despite this understanding, the specific role of DARS-AS1 in breast cancer remains underexplored. In this study, we employed quantitative reverse transcription-polymerase chain reaction to measure the expression levels of DARS-AS1 and miR-6835-3p. Functional assessments, including the cell invasion and CCK-8 assays, were conducted to investigate cellular behaviors. In addition, a luciferase reporter assay was employed to elucidate the mechanistic interaction between DARS-AS1 and miR-6835-3p. Notably, DARS-AS1 expression was elevated in breast cancer cell lines (MCF7 and MDA-MB-231) relative to the non-cancerous MCF-10A cells. Overexpression of DARS-AS1 enhanced cell growth and invasion in MDA-MB-231 breast cancer cells. Further investigation revealed that DARS-AS1 acts as a sponge for miR-6835-3p in breast cancer cells. Overexpression of miR-6835-3p inhibited luciferase activity, specifically in the presence of wild-type DARS-AS1, highlighting a direct interaction. Ectopic expression of DARS-AS1 suppressed miR-6835-3p in MDA-MB-231 cells. Concurrently, miR-6835-3p levels were downregulated in breast cancer cells, and miR-6835-3p exhibited a negative correlation with DARS-AS1 expression. Mechanistically, miR-6835-3p targeted ATF3 expression in breast cancer cells. Increased levels of DARS-AS1 were found to enhance cellular proliferation and invasion by modulating ATF3. Our findings indicate that DARS-AS1 acts as an oncogene in breast cancer, partially through regulation of the miR-6835-3p/ATF3 pathway. This study provides valuable insights into the molecular mechanisms contributing to breast cancer progression, offering potential targets for therapeutic interventions.

Keywords
miR-6835-3p
ATF3
LncRNA DARS-AS1
Breast cancer
Funding
No funds were received for this study.
References
  1. Polyak K. Heterogeneity in breast cancer. J Clin Investig. 2011;121:3786-3788. doi: 10.1172/JCI60534

 

  1. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874. doi: 10.1073/pnas.191367098

 

  1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752. doi: 10.1038/35021093

 

  1. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4-13. doi: 10.3121/cmr.2009.825

 

  1. Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014;15:e625-e634. doi: 10.1016/S1470-2045(14)70364-X

 

  1. Gao Y, Shang S, Guo S, et al. Lnc2Cancer 3.0: An updated resource for experimentally supported lncRNA/circRNA cancer associations and web tools based on RNA-seq and scRNA-seq data. Nucleic Acids Res. 2021;49:D1251-D1258. doi: 10.1093/nar/gkaa1006

 

  1. Han L, Yan Y, Zhao L, et al. LncRNA HOTTIP facilitates the stemness of breast cancer via regulation of miR-148a-3p/ WNT1 pathway. J Cell Mol Med. 2020;24:6242-6252. doi: 10.1111/jcmm.15261

 

  1. Hunt SE, McLaren W, Gil L, et al. Ensembl variation resources. Database (Oxford). 2018;2018:bay119. doi: 10.1093/database/bay119

 

  1. Kong X, Duan Y, Sang Y, et al. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 2019;234:9105-9117. doi: 10.1002/jcp.27587

 

  1. Lakshmi S, Hughes TA, Priya S. Exosomes and exosomal RNAs in breast cancer: A status update. Eur J Cancer. 2021;144:252-268. doi: 10.1016/j.ejca.2020.11.033

 

  1. Sun J, Zheng G, Gu Z, Guo Z. MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2. J Neurooncol. 2015;122:481-489. doi: 10.1007/s11060-015-1753-x

 

  1. Cheetham SW, Gruhl F, Mattick JS, Dinger ME. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108:2419-2425. doi: 10.1038/bjc.2013.233

 

  1. Shin VY, Chu KM. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014;20:10432-10439. doi: 10.3748/wjg.v20.i30.10432

 

  1. Huang J, Zhang SY, Gao YM, et al. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: Potential biomarkers and therapeutic targets. Cell Prolif. 2014;47:277-286. doi: 10.1111/cpr.12109

 

  1. Tay HL, Plank M, Collison A, Mattes J, Kumar RK, Foster PS. MicroRNA: Potential biomarkers and therapeutic targets for allergic asthma? Ann Med. 2014;46:633-639. doi: 10.3109/07853890.2014.958196

 

  1. Xiong DD, Li ZY, Liang L, et al. The LncRNA NEAT1 accelerates lung adenocarcinoma deterioration and binds to Mir-193a-3p as a competitive endogenous RNA. Cell Physiol Biochem. 2018;48:905-918. doi: 10.1159/000491958

 

  1. Zhang S, Ma H, Zhang D, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9:742. doi: 10.1038/s41419-018-0793-5

 

  1. Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8:1015. doi: 10.3390/cells8091015

 

  1. Cai Y, Yu X, Hu S, Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 2009;7:147-154. doi: 10.1016/S1672-0229(08)60044-3

 

  1. Cuperus JT, Fahlgren N, Carrington JC. Evolution and functional diversification of MIRNA genes. Plant Cell. 2011;23:431-442. doi: 10.1105/tpc.110.082784

 

  1. Reddy KB. MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015;15:38. doi: 10.1186/s12935-015-0185-1

 

  1. Hill M, Tran N. miRNA interplay: Mechanisms and consequences in cancer. Dis Model Mech. 2021;14:dmm047662. doi: 10.1242/dmm.047662

 

  1. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282-289. doi: 10.1016/j.drudis.2012.10.002

 

  1. Wang KJ, Zhao X, Liu YZ, et al. Circulating MiR-19b-3p, MiR- 134-5p and MiR-186-5p are promising novel biomarkers for early diagnosis of acute myocardial infarction. Cell Physiol Biochem. 2016;38:1015-1029. doi: 10.1159/000443053

 

  1. Feng Z, Zhang L, Wang S, Hong Q. Circular RNA circDLGAP4 exerts neuroprotective effects via modulating miR-134-5p/CREB pathway in Parkinson’s disease. Biochem Biophys Res Commun. 2020;522:388-394. doi: 10.1016/j.bbrc.2019.11.102

 

  1. Chi J, Liu T, Shi C, et al. Long non-coding RNA LUCAT1 promotes proliferation and invasion in gastric cancer by regulating miR-134-5p/YWHAZ axis. Biomed Pharmacother. 2019;118:109201. doi: 10.1016/j.biopha.2019.109201

 

  1. He J, Yang T, He W, et al. Liver X receptor inhibits the growth of hepatocellular carcinoma cells via regulating HULC/miR- 134-5p/FOXM1 axis. Cell Signal. 2020;74:109720. doi: 10.1016/j.cellsig.2020.109720

 

  1. Zhong BZ, Wang Q, Liu F, He JL, Xiong Y, Cao J. Effects of miR-384 and miR-134-5p acting on YY1 signaling transduction on biological function of gastric cancer cells. Onco Targets Ther. 2020;13:9631-9641. doi: 10.2147/OTT.S259988

 

  1. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297. doi: 10.1016/S0092-8674(04)00045-5

 

  1. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38:228-233. doi: 10.1038/ng1725

 

  1. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132:4653-4662. doi: 10.1242/dev.02073

 

  1. Hu K, Liang M. Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN. In Vitro Cell Dev Biol Anim. 2017;53:149-156. doi: 10.1007/s11626-016-0093-2

 

  1. Wang Y, He X, Yu Q, Eng C. Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas. Hum Mol Genet. 2013;22:2263-2272. doi: 10.1093/hmg/ddt077

 

  1. Wang Y, Radhakrishnan D, He X, Peehl DM, Eng C. Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation. J Clin Endocrinol Metab. 2013;98:E586-E594. doi: 10.1210/jc.2012-3490

 

  1. Zou A, Liu X, Mai Z, et al. LINC00472 acts as a tumor suppressor in NSCLC through KLLN-mediated p53-signaling pathway via MicroRNA-149-3p and MicroRNA-4270. Mol Ther Nucleic Acids. 2019;17:563-577. doi: 10.1016/j.omtn.2019.06.003

 

  1. David CJ, Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19:419-435. doi: 10.1038/s41580-018-0007-0

 

  1. Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 2005;21:659-693. doi: 10.1146/annurev.cellbio.21.022404.142018

 

  1. Jiang M, Chen J, Zhang W, et al. Interleukin-6 trans-signaling pathway promotes immunosuppressive myeloid-derived suppressor cells via suppression of suppressor of cytokine signaling 3 in breast cancer. Front Immunol. 2017;8:1840. doi: 10.3389/fimmu.2017.01840
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Share
Back to top
Cancer Plus, Electronic ISSN: 2661-3840 Print ISSN: 2661-3832, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept